159 related articles for article (PubMed ID: 37203036)
1. Assessment of the efficacy of olopatadine 0.1% in the treatment of vernal keratoconjunctivitis in terms of clinical improvement based on total ocular symptom score and ocular surface disease index.
Mohan S; Kumar S; Kumar GP; Maheswari A; Bhatia A; Sagar A
Indian J Ophthalmol; 2023 May; 71(5):1822-1827. PubMed ID: 37203036
[TBL] [Abstract][Full Text] [Related]
2. To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital.
Sruthi V; Reddy RN; Sowmini K; Grace NS
Indian J Pharmacol; 2020; 52(6):476-481. PubMed ID: 33666188
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis.
Abelson MB; Turner D
Clin Ther; 2003 Mar; 25(3):931-47. PubMed ID: 12852709
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye.
Mah FS; O'Brien T; Kim T; Torkildsen G
Curr Med Res Opin; 2008 Feb; 24(2):441-7. PubMed ID: 18167176
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
Spangler DL; Abelson MB; Ober A; Gotnes PJ
Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis.
Katelaris CH; Ciprandi G; Missotten L; Turner FD; Bertin D; Berdeaux G;
Clin Ther; 2002 Oct; 24(10):1561-75. PubMed ID: 12462286
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.
Spangler DL; Bensch G; Berdy GJ
Clin Ther; 2001 Aug; 23(8):1272-80. PubMed ID: 11558863
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study.
Abelson MB; Gomes PJ; Vogelson CT; Pasquine TA; Gross RD; Turner FD; Wells DT; Bergamini MV; Robertson SM
Clin Ther; 2004 Aug; 26(8):1237-48. PubMed ID: 15476905
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis.
Ayyappanavar S; Sridhar S; Kumar K; Jayanthi CR; Gangasagara SB; Rathod BLS; Preethi B; Mittal P
Indian J Ophthalmol; 2021 Feb; 69(2):257-261. PubMed ID: 33463568
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.
Lanier BQ; Finegold I; D'Arienzo P; Granet D; Epstein AB; Ledgerwood GL
Curr Med Res Opin; 2004 Aug; 20(8):1227-33. PubMed ID: 15324525
[TBL] [Abstract][Full Text] [Related]
11. A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis.
Rosenwasser LJ; Mahr T; Abelson MB; Gomes PJ; Kennedy K
Allergy Asthma Proc; 2008; 29(6):644-53. PubMed ID: 19063816
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model.
Deschenes J; Discepola M; Abelson M
Acta Ophthalmol Scand Suppl; 1999; (228):47-52. PubMed ID: 10337433
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
Abelson MB; Greiner JV
Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
[TBL] [Abstract][Full Text] [Related]
14. [Comparative study between 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of vernal keratoconjunctivitis].
Hida WT; Nogueira DC; Schaefer A; Dantas PE; Dantas MC
Arq Bras Oftalmol; 2006; 69(6):851-6. PubMed ID: 17273679
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
Berdy GJ; Stoppel JO; Epstein AB
Clin Ther; 2002 Jun; 24(6):918-29. PubMed ID: 12117082
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis.
Abelson MB; Gomes PJ; Pasquine T; Edwards MR; Gross RD; Robertson SM
Allergy Asthma Proc; 2007; 28(4):427-33. PubMed ID: 17883910
[TBL] [Abstract][Full Text] [Related]
17. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms.
Lanier BQ; Gross RD; Marks BB; Cockrum PC; Juniper EF
Ann Allergy Asthma Immunol; 2001 Jun; 86(6):641-8. PubMed ID: 11428736
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
Mah FS; Rosenwasser LJ; Townsend WD; Greiner JV; Bensch G
Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
[TBL] [Abstract][Full Text] [Related]
19. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.
Abelson MB; Spitalny L
Am J Ophthalmol; 1998 Jun; 125(6):797-804. PubMed ID: 9645717
[TBL] [Abstract][Full Text] [Related]
20. Comparison of preservative-free ketotifen fumarate and preserved olopatadine hydrochloride eye drops in the treatment of moderate to severe seasonal allergic conjunctivitis.
Mortemousque B; Bourcier T; Khairallah M; Messaoud R; Brignole-Baudouin F; Renault D; Rebika H; Brémond-Gignac D;
J Fr Ophtalmol; 2014 Jan; 37(1):1-8. PubMed ID: 24388379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]